期刊文献+

非医学专业女大学生对人乳头状瘤病毒疫苗接种行为的质性研究 被引量:1

下载PDF
导出
摘要 目的了解非医学专业女大学生对于人乳头状瘤病毒(HPV)疫苗认知情况、影响接种促进及阻碍因素,为促进HPV疫苗在国内接种有效推广及传播提供相关依据。方法采用描述性质性研究的半结构访谈法对非医学专业在校大学生12人进行访谈并录音,录音转文本后用内容分析法分析资料,分类归纳主题。结果疫苗接种促进因素包括积极感知健康知识、周围群体的示范作用、父母决策授权和医疗健康提供者的专业建议;疫苗接种的阻碍因素包括局限的选择余地、自身经济能力不足和风险担忧。结论当前,普通大学生进行HPV疫苗接种的决策受多因素的影响,在决策形成过程中已接种人群和专业医生意见、父母授权起重要作用。学校及卫生机构开展广泛且正确的HPV疫苗知识宣传、政府提供相应的政策导向及支持、加强疫苗信息在人际间的有效传递、加快国产疫苗的研发可能是促进大学生加强HPV疫苗接种的有效方法。
出处 《中国乡村医药》 2020年第19期58-60,共3页
  • 相关文献

参考文献3

二级参考文献36

  • 1Jemal A, Bray F, Center MM, et al. Global Cancer Statistic [ J ]. CA Cancer J Clin,2011,61 ( 2 ) :69-90.
  • 2Siegel R,Nais hadham D,Jemal A. Cancer statistics[ J]. CA Cancer J Clin,2013,63( 1 ) :11-59.
  • 3Jin XW, Sikon A, Yen Lieberman B. Cervical cancer screening: Less testing,smarter testing [ J ]. Cleve Clin J Med, 2011,78 ( 11 ) : 737- 747.
  • 4Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infec- tions among US women and men:prevalence and incidence estimates, 2008[ J]. Sex Transm Dis,2013,40(3) :187-193.
  • 5Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV ( types 6, 11,16, 18 )recombinant vaccine in adult women 24 -45 years of age[ J]. Br J Cancer,2011,105 ( 1 ) :28-37.
  • 6Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV- 16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical in- traepithelial neoplasia :4-year end-of-study analysis of the randomised, double-blind PATRICIA trial[ J]. Lancet Oncol,2012,13( 1 ) :89-99.
  • 7Wheeler CM, CasteUsague X, Garland SM, et al. Cross-protective effi- cacy of HPV-16./18 AS04-adjuvanted vaccine against cervical infec- tion and precancer caused by non-vaccine oncogenic HPV types:4- year end-of-study analysis of the randomised, double-blind PATRI- CIA trial[ J]. Lancet Oncol,2012,13 ( 1 ) : 100-110.
  • 8Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial [ J ]. JAMA, 2013,309 ( 17 ) : 1793-1802.
  • 9Roteli-Martins CM,Daud P,DeBorba P,et al. Sustained immunoge- nicity and efficacy of the HPV-16/18 ASO4-adjuvanted vaccine: up to 8.4 years of follow-up [ J ]. Human Vaccin Immunother, 2012,8 (3) :390-397.
  • 10Dillner J,Kjaer SK,Wheeler CM ,et al. Four year efficacy of prophy- lactic human papillomavirus quadrivalent vaccine against low grade cervical,vulvar, and vaginal intraepithelial neoplasia and anogenital warts : randomised controlled trial [ J ]. BMJ,2010 ( 341 ) : c3493.

共引文献58

同被引文献17

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部